FUTURE DIRECTIONS IN BREAST CANCER DIAGNOSIS: THE EXPANDING LANDSCAPE OF LIQUID BIOPSY- BASED BIOMARKERS
Keywords:
Liquid biopsy, Breast cancer, Circulating tumor DNA (ctDNA), Non-coding RNAs, Extracellular vesicles (EVs)Abstract
Breast cancer diagnosis is advancing through liquid biopsy, a minimally invasive method analyzingtumor-derived biomarkers in blood. Circulating tumor DNA (ctDNA), CTCs, EVs, and ncRNAs offer real-time insights into tumor dynamics, resistance, and subtypes. ctDNA enables early detection of recurrence, while ncRNA signatures guide prognosis and therapy. Integration with genomic strategies, such as using PARP inhibitors in BRCA1/2-deficient tumors, enhances treatment precision. This approach exploits synthetic lethality, selectively killing cancer cells while sparing normal ones. Emerging AI-driven multi-omics platforms promise personalized monitoring. Together, these innovations are reshaping breast cancer care.
Downloads
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.